https://scholars.lib.ntu.edu.tw/handle/123456789/624043
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Chen, Ching-Tso | en_US |
dc.contributor.author | Feng, Yin-Hsun | en_US |
dc.contributor.author | Yen, Chia-Jui | en_US |
dc.contributor.author | Chen, San-Chi | en_US |
dc.contributor.author | Lin, Yun-Tzu | en_US |
dc.contributor.author | LI-CHUN LU | en_US |
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | YU-YUN SHAO | en_US |
dc.date.accessioned | 2022-10-28T01:16:46Z | - |
dc.date.available | 2022-10-28T01:16:46Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.issn | 1936-0541 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/624043 | - |
dc.description.abstract | The combination of atezolizumab and bevacizumab (Atezo-Bev) has become the standard first-line therapy for patients with advanced hepatocellular carcinoma (HCC), but the prognosis and treatment pattern after its treatment failure are unclear. | en_US |
dc.language.iso | en | en_US |
dc.publisher | SPRINGER | en_US |
dc.relation.ispartof | Hepatology international | en_US |
dc.subject | Albumin-Bilirubin (ALBI) grade; Cancer of the Liver Italian Program (CLIP) score; Child–Pugh classification; Failure of Atezo-Bev treatment; Hepatocellular carcinoma; Liver function reserve; Prognosis; Second-line therapy; Systemic therapy; Treatment pattern | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.title | Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment | en_US |
dc.type | journal article | en |
dc.type | review | en_US |
dc.identifier.doi | 10.1007/s12072-022-10392-x | - |
dc.identifier.pmid | 35986846 | - |
dc.identifier.scopus | 2-s2.0-85136572807 | - |
dc.identifier.isi | WOS:000842146200001 | - |
dc.identifier.url | https://scholars.lib.ntu.edu.tw/handle/123456789/623991 | - |
dc.relation.pages | 1199 | en_US |
dc.relation.journalvolume | 16 | en_US |
dc.relation.journalissue | 5 | en_US |
dc.relation.pageend | 1207 | en_US |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | journal article | - |
item.openairetype | review | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0001-8975-9491 | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。